中国实用医药
中國實用醫藥
중국실용의약
China Practical Medical
2015年
34期
13-14
,共2页
利妥昔单抗注射液%化疗%B细胞非霍奇金淋巴瘤%临床效果
利妥昔單抗註射液%化療%B細胞非霍奇金淋巴瘤%臨床效果
리타석단항주사액%화료%B세포비곽기금림파류%림상효과
Rituximab injection%Chemotherapy%B cell non-hodgkin's lymphoma%Clinical effect
目的 研究B细胞非霍奇金淋巴瘤运用利妥昔单抗注射液联合化疗治疗的临床效果.方法 128例B细胞非霍奇金淋巴瘤患者,将其随机分为对照组和观察组,各64例.对照组患者采用单纯性CHOP方案进行化疗,观察组患者采用利妥昔单抗注射液联合化疗的方法进行治疗,比较两组患者的临床治疗效果.结果 观察组总有效率90.63%高于对照组71.88%,差异有统计学意义(P<0.05);两组患者治疗过程中出现不良反应的情况比较,差异无统计学意义(P>0.05).结论 对B细胞非霍奇金淋巴瘤实施治疗时,选择利妥昔单抗注射液联合化疗治疗的临床效果显著,同时患者具有很好的耐受性,毒副作用不明显,适合在临床上推广使用.
目的 研究B細胞非霍奇金淋巴瘤運用利妥昔單抗註射液聯閤化療治療的臨床效果.方法 128例B細胞非霍奇金淋巴瘤患者,將其隨機分為對照組和觀察組,各64例.對照組患者採用單純性CHOP方案進行化療,觀察組患者採用利妥昔單抗註射液聯閤化療的方法進行治療,比較兩組患者的臨床治療效果.結果 觀察組總有效率90.63%高于對照組71.88%,差異有統計學意義(P<0.05);兩組患者治療過程中齣現不良反應的情況比較,差異無統計學意義(P>0.05).結論 對B細胞非霍奇金淋巴瘤實施治療時,選擇利妥昔單抗註射液聯閤化療治療的臨床效果顯著,同時患者具有很好的耐受性,毒副作用不明顯,適閤在臨床上推廣使用.
목적 연구B세포비곽기금림파류운용리타석단항주사액연합화료치료적림상효과.방법 128례B세포비곽기금림파류환자,장기수궤분위대조조화관찰조,각64례.대조조환자채용단순성CHOP방안진행화료,관찰조환자채용리타석단항주사액연합화료적방법진행치료,비교량조환자적림상치료효과.결과 관찰조총유효솔90.63%고우대조조71.88%,차이유통계학의의(P<0.05);량조환자치료과정중출현불량반응적정황비교,차이무통계학의의(P>0.05).결론 대B세포비곽기금림파류실시치료시,선택리타석단항주사액연합화료치료적림상효과현저,동시환자구유흔호적내수성,독부작용불명현,괄합재림상상추엄사용.
Objective To research clinical effect by rituximab injection combined with chemotherapy in the treatment of B cell non-hodgkin's lymphoma.Methods A total of 128 patients with B cell non-hodgkin's lymphoma were randomly divided into control group and observation group, with 64 cases in each group. The control group received single CHOP regimen for chemotherapy, and the observation group received rituximab injection combined with chemotherapy for treatment. Clinical effects of the two groups were compared.Results The observation group had higher total effective rate as 90.63% than 71.88% of the control group, and their difference had statistical significance (P<0.05). The difference of adverse reactions during treatment had no statistical significance between the two groups (P>0.05).Conclusion Implement of rituximab injection combined with chemotherapy provides precise clinical effect in the treatment of B cell non-hodgkin's lymphoma. This method contains good compliance and slight adverse reactions, and it is worthy of clinical promotion and application.
